Search Results - "Clopès, Ana"

Implementing Risk-Sharing Arrangements for Innovative Medicines: The Experience in Catalonia (Spain) by Guarga, Laura, Gasol, Montse, Reyes, Anna, Roig, Marta, Alonso, Enric, Clopés, Ana, Delgadillo, Joaquim

“…Publications assessing health and economic outcomes of risk-sharing arrangements (RSAs) are limited. Better knowledge of these outcomes would shed light on the…”
Get full text

Simultaneous determination of five cytotoxic drugs in surface wiped samples using liquid chromatography and tandem mass spectrometry for the control of environmental contamination in a comprehensive cancer centre by Gonzalo, Núria, Rey, Montse, Fontanals, Sandra, Quer, Nuri, Clopés, Ana, Muñoz, Carme

“…The most common strategy to assess the occupational exposure risk to hazardous drugs in cancer healthcare settings is by monitoring environmental contamination…”
Get full text

Clinical practice guidelines for the optimization of hemato-oncological care: the ICOPraxis by Jordán de Luna, Consuelo, Fernández, Esteve, Mesía, Ricard, Clopés, Ana

“…Introduction The Catalan Institute of Oncology (ICO) is a Comprehensive Cancer Center (CCC) responsible for the oncological care of 46% of the Catalan…”
Get full text

Real‐world treatment outcomes of medicines used in special situations (off‐label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution by Fontanals, Sandra, Esteve, Anna, González, Andrea, Ibáñez, Cristina, Martínez, Javier, Mesía, Ricard, Clopés, Ana

“…Purpose Medicines in special situations (MSS) refer to off‐label or to unlicensed drugs under investigation (compassionate use). Our objectives were to…”
Get full text

Real‐world treatment outcomes of immune checkpoint inhibitors used off‐label in oncology: A comprehensive cancer institution experience by Fontanals, Sandra, Esteve, Anna, González, Andrea, Ibáñez, Cristina, Mesía, Ricard, Clopés, Ana

“…Off‐label use (OLU) is quite common in oncology due to the complexity of cancer and the time‐consuming regulatory process. However, outcomes of OLU in cancer…”
Get full text

An international comparative analysis and roadmap to sustainable biosimilar markets by Alnaqbi, Khalid A., Bellanger, Agnès, Brill, Alex, Castañeda-Hernández, Gilberto, Clopés Estela, Ana, Delgado Sánchez, Olga, García-Alfonso, Pilar, Gyger, Pius, Heinrich, Daniel, Hezard, Germain, Kakehasi, Adriana, Koehn, Cheryl, Mariotte, Olivier, Mennini, Francesco, Mayra Pérez-Tapia, Sonia, Pistollato, Michele, Saada, Rowan, Sasaki, Tadanori, Tambassis, George, Thill, Marc, Werutsky, Gustavo, Wilsdon, Tim, Simoens, Steven

“…Background: Although biosimilar uptake has increased (at a variable pace) in many countries, there have been recent concerns about the long-term sustainability…”
Get full text

Colorectal Cancer Screening Programme in Spain: Results of Key Performance Indicators After Five Rounds (2000–2012) by Binefa, Gemma, Garcia, Montse, Milà, Núria, Fernández, Esteve, Rodríguez-Moranta, Francisco, Gonzalo, Núria, Benito, Llúcia, Clopés, Ana, Guardiola, Jordi, Moreno, Víctor

“…Effective quality assurance is essential in any screening programme. This article provides a unique insight into key quality indicators of five rounds of the…”
Get full text

COVID-19 among workers of a comprehensive cancer centre between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain by Peremiquel-Trillas, Paula, Saura-Lázaro, Anna, Benavente-Moreno, Yolanda, Casabonne, Delphine, Loureiro, Eva, Cabrera, Sandra, Duran, Angela, Garrote, Lidia, Brao, Immaculada, Trelis, Jordi, Galán, Maica, Soler, Francesc, Julià, Joaquim, Cortasa, Dolça, Domínguez, Maria Ángeles, Albasanz-Puig, Adaia, Gudiol, Carlota, Ramírez-Tarruella, Dolors, Muniesa, Joan, Rivas, Juan Pedro, Muñoz-Montplet, Carles, Sedano, Ana, Plans, Àngel, Calvo-Cerrada, Beatriz, Calle, Candela, Clopés, Ana, Carnicer-Pont, Dolors, Alemany, Laia, Fernández, Esteve

“…ObjectivesPatients with cancer are at higher risk for severe COVID-19 infection. COVID-19 surveillance of workers in oncological centres is crucial to assess…”
Get full text

Clinical End Points and Relevant Clinical Benefits in Advanced Colorectal Cancer Trials by García, Margarita, Navarro, Valentín, Clopés, Ana

“…Discussion of which variable represents the benefits derived from the adoption of a new treatment in a more reliable manner is of vital importance, both for…”
Get full text

Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia by Reyes-Travé, Anna, Guarga-Solé, Laura, Roig-Izquierdo, Marta, Alonso-Pérez, Enrique, Clopés-Estela, Ana, Delgadillo-Duarte, Joaquín

“…Pharmaceutical risk-sharing arrangements have emerged as a reasonable tool to promote sustainable access to innovative medicines with uncertain clinical…”
Get full text

Impact on budget of new drugs for colorectal cancer treatment by Corral, M Julieta, Clopès, Ana, Navarro, Matilde, Germà, Josep Ramon, Borràs, Josep Maria

“…To assess the impact on the medicines budget of the introduction of new treatments in colorectal cancer, as monoclonal antibodies cetuximab and bevacizumab and…”
Get more information

Survey of oncohematological pharmaceutical care situation in Spain by Martínez-Bautista, María José, Mangues-Bafalluy, Irene, Cajaraville-Ordoñana, Gerardo, Carreras-Soler, María Josep, Clopés-Estela, Ana, Moreno-Martínez, Estela

“…To learn about the baseline of Oncohematological Pharmacy Units in Spanish hospitals in order to identify areas for  improvement. A survey in line with the…”
Get more information

Pharmacotherapeutic management of advanced therapy medicinal products by Poveda-Andrés, José Luis, Ruiz-Caldes, María José, Carreras-Soler, María José, Clopés-Estela, Ana, Flores-Moreno, Sandra, García-Pellicer, Javier, Giráldez-Quiroga, Míriam, López-Briz, Eduardo, Lozano-Blázquez, Ana, Megías-Vericat, Juan Eduardo, Tordera-Baviera, María, Valero-García, Silvia

“…Advanced therapy medicinal products have emerged In recent years as new pharmacotherapeutic strategies. In this context, hospital pharmacy services have had to…”
Get full text

Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations by García, Margarita, Clopés, Ana, Bruna, Jordi, Martínez, María, Fort, Eduard, Gil, Miguel

“…Chemotherapy is assuming an increasingly important role in the treatment of malignant gliomas, of which temozolomide (TMZ) is a key part. TMZ belongs to a…”
Get full text

Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages by Del Río-Valencia, Juan Carlos, Asensi-Díez, Rocío, Villalobos-Torres, Lorenzo, Clopés-Estela, Ana, Fraga-Fuentes, M ª Dolores

“…The economic evaluation of the drug olaratumab is carried out in the treatment of soft tissue sarcoma. The data were analyzed following the recommendations…”
Get more information

DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol by Torres, Sara Otero, Pérez, Olalla Montero, Mauriz, Rosa Rodríguez, Casamartina, Eduard Fort, Martínez, Sandra Fontanals, Estela, Ana Clopés

“…The increased risk of severe and life-threatening toxicity in patients with dihydropyridine dehydrogenase (DPD) deficiency, under treatment with…”
Get full text

Interacción entre tratamientos oncológicos y soporte nutricional by Fort Casamartina, Eduard, Arribas Hortiguela, Lorena, Bleda Pérez, Carmen, Muñoz Sánchez, Carme, Peiro Martínez, Imma, Perayre Badía, María, Clopés Estela, Ana

“…Durante la última década, el conocimiento de nuevos mecanismos implicados en el desarrollo del cáncer ha permitido el diseño de nuevos fármacos para su…”
Get full text

Centralization and automation of non-toxic drug reconstitution in the pharmacy: a strengths, weaknesses, opportunities, and threats analysis by Crul, Mirjam, Polidori, Carlo, Paolucci, Demis, Lowey, Andrew, Ølgaard McNulty, Helle, Rieutord, André, Salinas Silva, Paola, Clopes, Ana, Bredesen Hatlelid, Liv, Leoni, Simone

Get full text

Posicionamiento del farmacéutico de hospital ante la utilización de medicamentos en condiciones diferentes a las autorizadas by Delgado, Olga, Puigventós, Francesc, Clopés, Ana

Get full text

Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer by Clopes, Ana, Gasol, Montse, Cajal, Rosana, Segú, Luis, Crespo, Ricard, Mora, Ramón, Simon, Susana, Cordero, Luis A, Calle, Candela, Gilabert, Antoni, Germà, Josep R

“…In 2011 the first payment-by-results (PbR) scheme in Catalonia was signed between the Catalan Institute of Oncology (ICO), the Catalan Health Service, and…”
Get more information